BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura

Overview

Journal Case Rep Med

Publisher Wiley

Specialty General Medicine

Date 2022 Apr 25

PMID 35464782

Authors

A K Ghosh

S Bhushan

L D R Lopez

D Sampat

Z Salah

C A Hatoum

Affiliations

Soon will be listed here.

Abstract

Immune thrombocytopenic purpura (ITP) has been reported following vaccinations such as MMR as well as after viral infections such as hepatitis C and HIV. Few case reports have been reported of ITP after COVID-19 infections and COVID-19 vaccines. Herein, we present a patient who presented with severe ITP with a platelet count of 0 after receiving the second dose of the BNT162b2 mRNA COVID-19 vaccine (also known as the Pfizer BioNTech). She subsequently recovered with a prolonged treatment course.

Citing Articles

COVID-19-induced immune thrombocytopenia management approach: A case report and literature review.

Alahwal H, Alsharif M, Alsharif M, Almohammadi A, Al-Marzouki A, Barefah A Clin Case Rep. 2024; 12(6):e9070.

PMID: 38883219 PMC: 11176723. DOI: 10.1002/ccr3.9070.

Case mistaken for leukemia after mRNA COVID-19 vaccine administration: A case report.

Lee S, Park C, Park S, Lee H World J Clin Cases. 2022; 10(33):12268-12277.

PMID: 36483810 PMC: 9724544. DOI: 10.12998/wjcc.v10.i33.12268.

A Systematic Review of Reported Cases of Immune Thrombocytopenia after COVID-19 Vaccination.

Saluja P, Amisha F, Gautam N, Goraya H Vaccines (Basel). 2022; 10(9).

PMID: 36146522 PMC: 9500907. DOI: 10.3390/vaccines10091444.

References

Shah S, Dolkar S, Mathew J, Vishnu P . COVID-19 vaccination associated severe immune thrombocytopenia. Exp Hematol Oncol. 2021; 10(1):42. PMC: 8280588. DOI: 10.1186/s40164-021-00235-0. View

France E, Glanz J, Xu S, Hambidge S, Yamasaki K, Black S . Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008; 121(3):e687-92. DOI: 10.1542/peds.2007-1578. View

Julian J, Mathern D, Fernando D . Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine. Ann Emerg Med. 2021; 77(6):654-656. PMC: 7879100. DOI: 10.1016/j.annemergmed.2021.02.011. View

Cooper N, Bussel J . The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006; 133(4):364-74. DOI: 10.1111/j.1365-2141.2006.06024.x. View

Nazi I, Kelton J, Larche M, Snider D, Heddle N, Crowther M . The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013; 122(11):1946-53. PMC: 3773242. DOI: 10.1182/blood-2013-04-494096. View

Jasaraj R, Shrestha D, Gaire S, Kassem M . Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female. Cureus. 2021; 13(8):e16871. PMC: 8414938. DOI: 10.7759/cureus.16871. View

Lee E, Cines D, Gernsheimer T, Kessler C, Michel M, Tarantino M . Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021; 96(5):534-537. PMC: 8014568. DOI: 10.1002/ajh.26132. View

Ganzel C, Ben-Chetrit E . Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine. Isr Med Assoc J. 2021; 23(6):341. View

Cecinati V, Principi N, Brescia L, Giordano P, Esposito S . Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother. 2013; 9(5):1158-62. PMC: 3899154. DOI: 10.4161/hv.23601. View

10.

Idogun P, Ward M, Teklie Y, Wiese-Rometsch W, Baker J . Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration. Cureus. 2021; 13(5):e14853. PMC: 8176657. DOI: 10.7759/cureus.14853. View

11.

Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

12.

Jawed M, Khalid A, Rubin M, Shafiq R, Cemalovic N . Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP. Open Forum Infect Dis. 2021; 8(7):ofab343. PMC: 8294682. DOI: 10.1093/ofid/ofab343. View

13.

Akiyama H, Kakiuchi S, Rikitake J, Matsuba H, Sekinada D, Kozuki Y . Immune thrombocytopenia associated with Pfizer-BioNTech's BNT162b2 mRNA COVID-19 vaccine. IDCases. 2021; 25:e01245. PMC: 8336989. DOI: 10.1016/j.idcr.2021.e01245. View

14.

Fueyo-Rodriguez O, Valente-Acosta B, Jimenez-Soto R, Neme-Yunes Y, Inclan-Alarcon S, Trejo-Gonzalez R . Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination. BMJ Case Rep. 2021; 14(5). PMC: 8169472. DOI: 10.1136/bcr-2021-242220. View

15.

Cines D, Blanchette V . Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13):995-1008. DOI: 10.1056/NEJMra010501. View

16.

Bhattacharjee S, Banerjee M . Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review. SN Compr Clin Med. 2020; 2(11):2048-2058. PMC: 7501509. DOI: 10.1007/s42399-020-00521-8. View

17.

Schweizer C, Reu F, Ho A, Hensel M . Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab. Ann Hematol. 2007; 86(10):711-7. DOI: 10.1007/s00277-007-0335-1. View